No Link between the TFPI V264M Mutation and Venous Thromboembolic Disease

Thromb Haemost 1999; 82(01): 159-160
DOI: 10.1055/s-0037-1614654

Letters to the Editor

Schattauer GmbH

Authors

Emmanuel Arnaud

¹From the INSERM U428 and Centre Claude Bernard de Recherche sur les Maladies Vasculaires, CHU Broussais, Paris, France
Didier Moatti

²From the INSERM U479 and Service d’Hématologie et d’Immunologie, CHU Xavier Bichat, Paris, France
Joseph Emmerich

¹From the INSERM U428 and Centre Claude Bernard de Recherche sur les Maladies Vasculaires, CHU Broussais, Paris, France
Martine Aiach

¹From the INSERM U428 and Centre Claude Bernard de Recherche sur les Maladies Vasculaires, CHU Broussais, Paris, France
Dominique de Prost

²From the INSERM U479 and Service d’Hématologie et d’Immunologie, CHU Xavier Bichat, Paris, France

References
1 Broze Jr GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
2 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterisation of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
3 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
4 Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, Garbarz M, Dhermy D, Arveiler D, Evans A, Luc G, Ruidavets J-B, Ollivier V, Hakim J, Aumont MC, de Prost D. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects. Impact of the V264M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
5 Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-10.